Abatacept induces clinical improvement in patients with severe systemic sclerosis

Scandinavian Journal of Rheumatology

Volumn 43, Issue 4, 2014, Pages 342-345

  De Paoli, F V ^a,b   Nielsen, B D ^a   Rasmussen, F ^a   Deleuran, B ^a,b   Sondergaard K ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT;

ADULT; AUTOIMMUNE DISEASE; CASE REPORT; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LETTER; LUNG FUNCTION; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME; YOUNG ADULT;

ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; IMMUNOCONJUGATES; MIDDLE AGED; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905443072     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2013.812238     Document Type: Letter

References (10)

1. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis: quantification, subtyping, and clinical correlations. Arthritis Rheum 1984:27;645-53.
2. Sondergaard K, Stengaard-Pedersen K, Zachariae H, Heickendorff L, Deleuran M, Deleuran B. Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL- 2R) in scleroderma skin. Br J Rheumatol 1998:37;304-10.
3. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl JMed 2009;360:1989-2003.
4. Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trail evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002:46;1470-9.
5. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980:23;581-90.
6. Joerring S, Jensen LT, Andersen GR, Johansen JS. Types I and III procollagen extension peptides in serum respond to fracture in humans. Arch Orthop Trauma Surg 1992:111;265-7.
7. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma.NEngl J Med 2006:354;2655-66.
8. Shand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, Black CM, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis. Arthritis Rheum 2007:56;2422-31.
9. Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, et al. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum 2009:60;2490-8.
10. Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011;378:498-506.